Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
Financially, Gyre had cash and cash equivalents totaling $15.9 million as of September 30, 2024. For the third quarter of ...
Ensenada, BC.- Hace apenas unas semanas, la Cofepris autorizó el uso de un innovador tratamiento para pacientes con fibrosis ...
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.
Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...
As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...
1don MSN
Se harán ensayos en vacunas de Covid, gripe A y el virus respiratorio sincitial GIRONA, 12 (EUROPA PRESS) La sociedad Pectus ...
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback